295 related articles for article (PubMed ID: 32976493)
1. De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics.
Giraud JS; Doisne M; Chan Hew Wai A; Majerholc C; Fourn E; Sejean K; Trichereau J; Bonan B; Zucman D
PLoS One; 2020; 15(9):e0239704. PubMed ID: 32976493
[TBL] [Abstract][Full Text] [Related]
2. De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.
Krentz HB; Campbell S; Lahl M; Gill MJ
HIV Med; 2019 Mar; 20(3):214-221. PubMed ID: 30632660
[TBL] [Abstract][Full Text] [Related]
3. Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
Krentz HB; Campbell S; Gill VC; Gill MJ
HIV Med; 2018 Apr; 19(4):290-298. PubMed ID: 29368401
[TBL] [Abstract][Full Text] [Related]
4. Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Montastruc JL; Sommet A
Fundam Clin Pharmacol; 2018 Aug; 32(4):450-458. PubMed ID: 29505661
[TBL] [Abstract][Full Text] [Related]
5. Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database.
Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Sommet A
Therapie; 2018; 73(3):257-266. PubMed ID: 29195713
[TBL] [Abstract][Full Text] [Related]
6. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
[TBL] [Abstract][Full Text] [Related]
7. Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.
Ramiro MA; Llibre JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):598-602. PubMed ID: 24139337
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.
Sweet DE; Altice FL; Cohen CJ; Vandewalle B
PLoS One; 2016; 11(1):e0147821. PubMed ID: 26808503
[TBL] [Abstract][Full Text] [Related]
9. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.
Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T
HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
Olalla J; Pérez-Stachowski J; Tortajada B; Del Arco A; Márquez E; De la Torre J; Nieto M; García de Lomas JM; Prada JL; García-Alegría J
BMC Pharmacol Toxicol; 2018 Oct; 19(1):63. PubMed ID: 30305176
[TBL] [Abstract][Full Text] [Related]
11. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
14. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
16. Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.
Hill A; Hill T; Jose S; Pozniak A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19497. PubMed ID: 25394006
[TBL] [Abstract][Full Text] [Related]
17. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
19. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
Stoll M; Kollan C; Bergmann F; Bogner J; Faetkenheuer G; Fritzsche C; Hoeper K; Horst HA; van Lunzen J; Plettenberg A; Reuter S; Rockstroh J; Stellbrink HJ; Hamouda O; Bartmeyer B;
PLoS One; 2011; 6(9):e23946. PubMed ID: 21931626
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
DeJesus E; Saleh S; Cheng S; van der Mey D; Becker C; Frey R; Unger S; Mueck W
Pulm Circ; 2019; 9(2):2045894019848644. PubMed ID: 30997864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
